BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview

2024/04/10 22:02:10				
Price 8.298 EUR				
Difference	0	-2.66% (-0.23)		


General attributes				
ISIN	CA0717341071			
Symbol	BHC			
Exchange	Tradegate			
Currency	EUR			
Sector	Chemical / Pharmaceutical / Health			
Security type	Stock			
Market cap (m)	3,002 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.262 EUR (400)
Ask (Ask size)	8.333 EUR (400)
Open	8.298 EUR
High	8.298 EUR
Low	8.298 EUR
Close (prev. day)	8.525 EUR
VWAP	8.96377 EUR
Volume (pcs)	-
Trading volume	-
Number of trades	1
Last size	-

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.



Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

đ,

on sector			
Date		Headline	Download
2024/04/03	80. 126 821 188	Global Equity Ratings	
2024/03/13	55. Let 27. 1%	Global Equity Ratings	
2024/02/22	80. 126 821 188	Global Equity Ratings	
2024/02/14	55. Let 27. 1%	Global Equity Ratings	
2024/01/23	80 Jan 80 Tes	Global Equity Ratings	




Details

2024/04/10 22:02:10					
Price					
8.298 EUR					
Difference	0	-2.66% (-0.23)			

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	Tradegate			
Currency	EUR			
Sector	Chemical / Pharmaceutical / Health			
Security type	Stock			
Market cap (m)	3,002 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.262 EUR (400)
Ask (Ask size)	8.333 EUR (400)
Open	8.298 EUR
High	8.298 EUR
Low	8.298 EUR
Close (prev. day)	8.525 EUR
VWAP	8.96377 EUR
Volume (pcs)	-
Trading volume	-
Number of trades	1
Last size	-

Performance and Risk						
	6m 1Y 3Y					
Perf (%)	+17.86%	+26.95%	-67.03%			
Perf (abs.)	+1.29	+1.81	-17.34			
Beta	1.75	1.30	1.81			
Volatility	41.81	52.84	71.41			



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	9.122 EUR (1,961)
Ø price 30 days Ø volume 30 days (pcs.)	8.810 EUR (1,774)
Ø price 100 days Ø volume 100 days (pcs.)	7.674 EUR (937)
Ø price 250 days Ø volume 250 days (pcs.)	7.443 EUR (791)
YTD High date	9.893 EUR (2024/03/28)
YTD Low date	7.051 EUR (2024/01/05)
52 Weeks High date	9.893 EUR (2024/03/28)
52 Weeks Low date	5.146 EUR (2023/05/08)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/04/ 10	22:02	8.298 EUR	0.00	1
Toronto Stock Exchange	2024/04/ 10	22:00	12.20 CAD	4.38	2,467
Stuttgart	2024/04/ 10	21:05	8.292 EUR	0.00	9
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/04/	22:00	8.92 USD	23.29	17,299



	10				
Munich	2024/04/ 10	08:03	8.611 EUR	0.00	2
Frankfurt	2024/04/ 10	08:10	8.453 EUR	0.00	2
Duesseldorf	2024/04/ 10	08:10	8.443 EUR	0.00	3
Berlin	2024/04/ 10	08:04	8.451 EUR	0.00	2



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Wellibers of Wallagement Board	
Joseph C. Papa	Chairman of Managing Board
Louis Yu	Member of Executive Committee
Tage Ramakrishna	Member of Executive Committee
Barbara Purcell	Member of Executive Committee
Christina Ackermann	Member of Executive Committee
Dennis Asharin	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Joseph Gordon	Member of Executive Committee
Kelly Webber	Member of Executive

Committee

Committee

Committee

Committee

Committee

Committee

Member of Executive

Paul S.

Sam Eldessouky

Herendeen

Robert Spurr

Scott Hirsch

Thomas Appio

Mombors of Management Roard

æ,

Board of directors	
John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Russel Robertson	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board
Thomas Ross	Member of Supervisory Board

